Drug pipeline
Explore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Inhibitor of nuclear factor kappa-B kinase subunit epsilon (IKBKE), also known as IKK-epsilon or IKK-i, is a noncanonical serine/threonine kinase belonging to the IkappaB kinase family. It plays a pivotal role in regulating both innate immune responses and oncogenic signaling pathways. Upon activation by viral infection or inflammatory cytokines, IKBKE phosphorylates key transcription factors, such as interferon regulatory factors 3 and 7 (IRF3/7) and NF-kappa-B subunits, to drive the expression of type I interferons and pro-inflammatory cytokines. In oncology, IKBKE acts as an oncogene that is frequently amplified or overexpressed in various malignancies, including breast, ovarian, pancreatic, and lung cancers, where it promotes cell survival, proliferation, metastasis, and chemoresistance. Consequently, IKBKE has emerged as an attractive therapeutic target. Small-molecule inhibitors, such as amlexanox and momelotinib, are being investigated for their ability to block IKBKE activity, thereby suppressing tumor growth and restoring sensitivity to therapies, as well as treating metabolic and autoimmune disorders.
Inhibition of the kinase activity of IKBKE, preventing the phosphorylation of downstream substrates such as IRF3, IRF7, and IkappaB-alpha, thereby blocking NF-kappa-B activation and type I interferon signaling.
5 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Inhibitor of nuclear factor kappa-B kinase subunit epsilon (IKBKE).